- Patients
- Clinical Research
- Clinical trials
- XL092-304
2024-06-21T07:51:13.815Z
XL092-304
XL092-304
Kidney cancer
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. Study detail: This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. Study detail: This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Kidney cancer
Study Phase
III
Trial registration
Number: NCT05678673
GenesisCare Location(s)
GenesisCare Cavalry Central Districts
GenesisCare Cavalry Central Districts
:::
GenesisCare Location(s)
Mark McGregor